Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRME
STRONG SELLPrime Medicine, Inc. · Healthcare · United States · $533M · Avg Vol: $12M/d
COMPANY DESCRIPTION
Prime Medicine, Inc. is a biotechnology company pioneering a new class of gene editing technology called Prime Editing to precisely correct a wide range of disease-causing mutations. The company's competitive moat is its innovative Prime Editing platform, which offers the potential for broader and more precise genetic correction than previous gene editing tools. It aims to develop therapies for a multitude of genetic diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3.0M | 4.6M | 55.3% | 4.0M | 9.0M | — | 94.9% |
| EPS | -4.19 | -2.18 | -1.65 | -1.35 | — | -1.19 | -0.99 | -0.84 | — |
| Shares | 97.2M | 97.4M | 131.2M | 180.5M | +85.7% | 180.6M | — | — | — |
| Debt | 28.7M | 13.6M | 40.8M | 116.4M | 59.4% | 114.5M | — | — | — |
| Equity | 316.3M | 133.1M | 153.1M | 120.9M | -27.4% | — | — | — | — |
| Op CF | -131.8M | -165.4M | -122.9M | -162.6M | — | -156.4M | — | — | — |
| Inv CF | -47.1M | 18.7M | 68.5M | -108.8M | — | — | — | — | — |
| Fin CF | 181.5M | 0.7M | 195.9M | 151.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRME are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRME | Prime Medicine, Inc.(you) | $533M | 3 | STRONG SELL |
| SPRY | ARS Pharmaceuticals, Inc. | $590M | 5 | STRONG SELL |
| RGNX | REGENXBIO Inc. | $623M | 7 | STRONG SELL |
| PROK | ProKidney Corp. | $453M | 7 | STRONG SELL |
| VSTM | Verastem, Inc. | $532M | 10 | STRONG SELL |
| OCGN | Ocugen, Inc. | $410M | 1 | STRONG SELL |
| ALT | Altimmune, Inc. | $539M | 12 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 7 | STRONG SELL |
| EIKN | Eikon Therapeutics, Inc. | $482M | 12 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%